Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price

Merck & Co., Inc. (NYSE: MRK) has cleared a key U.S. antitrust condition in its pending acquisition of Terns Pharmaceuticals, Inc. (NASDAQ: TERN), after the Hart-Scott-Rodino waiting period expired on April 23, 2026. The transaction is structured as a $53-per-share cash tender offer for all outstanding shares of Terns Pharmaceuticals, with the biotechnology company’s lead chronic myeloid leukemia candidate TERN-701 sitting at the center of the deal. The development matters because Merck & Co., Inc. is using acquisitions to broaden its oncology and hematology pipeline before future Keytruda patent pressure becomes a larger earnings question. With Merck & Co., Inc. recently trading below its 52-week high and Terns Pharmaceuticals trading close to the offer price, the market is treating the deal less as a surprise and more as a test of whether Merck can convert late-cycle capital allocation into durable pipeline value.

Why does Merck’s Terns acquisition matter for investors watching the post-Keytruda growth story?

The immediate event is procedural, but the strategic context is much larger. The expiry of the Hart-Scott-Rodino waiting period means U.S. antitrust review is no longer the most visible obstacle to Merck & Co., Inc.’s acquisition of Terns Pharmaceuticals. The tender offer still requires more than half of Terns Pharmaceuticals’ outstanding shares to be validly tendered, along with other closing conditions, but the regulatory clearance reduces execution friction and keeps the transaction on its intended path.

For investors, the acquisition sits inside a broader Merck question: how convincingly can the pharmaceutical group extend its growth story beyond Keytruda? Keytruda remains one of the most commercially important oncology products in the world, but no single blockbuster can carry valuation comfort forever. As patent timelines move closer, investors tend to examine every pipeline acquisition through a tougher lens. They are not only asking whether the asset is scientifically interesting. They are asking whether it can become large enough, differentiated enough, and durable enough to matter in Merck & Co., Inc.’s long-term earnings mix.

TERN-701 gives Merck & Co., Inc. a targeted hematology asset rather than another broad immuno-oncology extension. That is important because chronic myeloid leukemia is a treatment area where patients can remain on therapy for long periods, making durable efficacy and tolerability commercially meaningful. However, this also raises the bar. Merck is not buying a marketed product with established revenue. It is buying clinical-stage optionality, which means the deal’s strategic value will ultimately depend on data, positioning, and regulatory execution rather than the antitrust milestone itself.

What does TERN-701 add to Merck’s oncology strategy beyond headline deal value?

TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor being developed for certain patients with chronic myeloid leukemia. In plain business terms, Merck & Co., Inc. is adding a small-molecule hematology asset that could potentially compete in a category shaped by long treatment duration, physician familiarity with tyrosine kinase inhibitors, and demand for therapies that can address resistance or tolerability challenges.

That makes the acquisition more targeted than the headline valuation alone suggests. Merck is not simply buying “more oncology.” It is buying a possible foothold in a specific molecular segment of chronic myeloid leukemia treatment. If TERN-701 can show a clean enough efficacy and safety profile, it could give Merck a way to participate in a specialized but commercially resilient oncology market. If it fails to separate from existing options, the deal could become another reminder that pharmaceutical mergers and acquisitions often look cleaner in boardroom slides than in clinical readouts.

The competitive context matters. Chronic myeloid leukemia has already been transformed by tyrosine kinase inhibitor therapy, so physicians are not waiting for the first effective drug. They are looking for better sequencing options, improved tolerability, deeper molecular responses, and practical benefits for patients who are not well served by existing therapies. For Merck, therefore, the key question is not whether TERN-701 works in a general sense. The key question is whether TERN-701 can be positioned as meaningfully different in a market that already has established treatment logic.

How does the tender offer structure shape the market signal around Terns Pharmaceuticals stock?

Terns Pharmaceuticals’ share price trading close to the $53 cash offer indicates that investors broadly expect the transaction to close, or at least see limited near-term spread risk. That is typical when a deal has cleared a meaningful regulatory condition and the offer price is fixed. The stock’s proximity to the offer price also suggests that the market is no longer valuing Terns Pharmaceuticals as a standalone speculative biotech story. It is now being valued mainly as a merger-arbitrage situation.

That has two implications. First, the upside for Terns Pharmaceuticals shareholders is largely capped unless a rival bidder emerges or the transaction terms change. Second, the downside becomes tied to deal completion risk rather than ordinary biotech volatility. This is a very different investor setup from the period before Merck & Co., Inc. entered the picture, when Terns Pharmaceuticals’ valuation depended more directly on clinical optimism, cash runway, and investor appetite for small-cap biotechnology risk.

For Merck & Co., Inc., the share price signal is also useful. A tight spread near the offer price reduces noise around whether the deal will happen and allows investors to focus on the real strategic question: whether Merck is paying an acceptable price for the probability-weighted value of TERN-701. In pharmaceutical dealmaking, the market often gives acquirers limited credit upfront because development risk remains. That appears to be the case here. The transaction may be strategically sensible, but it still needs clinical validation before it can change the Merck growth narrative in a lasting way.

Why is Merck willing to buy clinical-stage risk instead of waiting for later data?

The logic is simple, but uncomfortable: waiting for cleaner data usually means paying a much higher price. Large pharmaceutical companies often acquire clinical-stage assets before uncertainty disappears because the most attractive assets become increasingly expensive as evidence strengthens. If TERN-701 later produces stronger data in chronic myeloid leukemia, Merck & Co., Inc. could have faced a more competitive auction or a much richer valuation.

That early-move strategy can work when the buyer has strong scientific conviction and the acquired asset fits a clear portfolio gap. Merck already has substantial oncology infrastructure, clinical development capability, regulatory experience, and global commercialization reach. Those capabilities can increase the value of a clinical-stage asset that might otherwise face funding, trial execution, or launch constraints as an independent biotechnology company.

However, buying early also concentrates scientific risk. TERN-701 still has to show that its mechanism can translate into clinical and commercial relevance. Phase 1/2 development can support enthusiasm, but it does not eliminate uncertainty around durability, adverse events, dose optimization, competitive positioning, or regulatory pathway design. Merck is effectively choosing to absorb development risk now in exchange for owning the asset before the market has full visibility. That is disciplined only if the science holds.

What does this deal reveal about biotech M&A appetite in oncology and hematology?

The Merck and Terns Pharmaceuticals transaction reinforces a larger pattern in biopharma: large pharmaceutical companies are still willing to pay for focused oncology assets when the mechanism, intellectual property, and commercial pathway appear attractive. Even in a selective funding environment for smaller biotechnology companies, assets that can plug strategic gaps for larger companies remain highly bankable.

This is particularly relevant in hematology, where targeted therapies can create durable franchises without needing the huge patient populations associated with mass-market primary care drugs. Chronic myeloid leukemia is not the biggest oncology category by patient volume, but its treatment dynamics can support meaningful commercial value if a product earns physician trust and fits clearly into sequencing decisions. That is why a single clinical-stage asset can justify serious acquisition interest.

The second-order consequence is that other biotechnology companies with differentiated hematology assets may attract closer investor attention. Merck’s move signals that strategic buyers are not only chasing obesity, immunology, or antibody-drug conjugate assets. They are still interested in precision oncology programs where mechanism, market structure, and development feasibility align. For smaller biotechs, that is encouraging. For buyers, it also means competition for clean, differentiated assets may stay intense.

How should investors read MRK stock performance against the strategic significance of the Terns deal?

Merck & Co., Inc. recently traded around $111.90, below its 52-week high of $125.14 but well above its 52-week low of $73.31. That positioning tells a useful story. The stock is not distressed, but investors are also not assigning runaway enthusiasm to every pipeline-building move. The market appears to be balancing Merck’s current earnings strength, Keytruda concentration risk, acquisition spending, and the uncertain payback timeline for clinical-stage assets.

The Terns Pharmaceuticals deal is unlikely to move Merck & Co., Inc. stock dramatically on its own because it does not add immediate revenue. It is a strategic investment in future optionality. That means the stock impact will likely be absorbed through a longer investor debate about whether Merck is assembling enough credible assets to support revenue growth later in the decade.

The deal also comes with capital allocation scrutiny. Merck is large enough to absorb a transaction of this size, but every acquisition made before a patent cliff is judged with extra suspicion. Investors will want to see whether management is buying assets with genuine differentiation or merely filling pipeline anxiety with expensive deals. That distinction will not be settled by the closing of the transaction. It will be settled by clinical data and eventual regulatory progress.

What could go wrong after Merck completes the Terns Pharmaceuticals acquisition?

The first risk is clinical differentiation. TERN-701 may show activity but still fail to demonstrate enough advantage over existing therapies to justify strong adoption. In a mature treatment category such as chronic myeloid leukemia, incremental efficacy may not be enough if safety, tolerability, sequencing logic, or payer support are not compelling.

The second risk is development timing. Even if the asset remains promising, Merck will need to move it through later-stage development while maintaining trial quality and regulatory clarity. Any delay, ambiguous readout, or safety signal could weaken the investment case. In oncology, time is not just a development variable. It is a competitive variable. Other companies do not pause their pipelines while Merck integrates Terns Pharmaceuticals.

The third risk is strategic overdependence on dealmaking. Acquisitions can strengthen a pipeline, but they cannot replace internal productivity. Merck & Co., Inc. needs acquired assets and internally developed programs to work together if it wants investors to believe the post-Keytruda transition is under control. TERN-701 may become a useful part of that bridge, but it cannot carry the full burden by itself. That is the sober part of the story, and probably the most important one.

What should executives and investors watch next as Merck moves toward closing the Terns deal?

The next visible milestone is the tender offer outcome. If more than 50 percent of Terns Pharmaceuticals’ outstanding shares are tendered and remaining conditions are satisfied, Merck & Co., Inc. can move closer to completing the acquisition. That would shift the story from deal execution to clinical execution almost immediately.

After closing, the most important signals will come from TERN-701 development updates. Investors should watch dose selection, response durability, safety profile, trial design, and how Merck frames the asset within its broader hematology strategy. Language around patient segmentation, comparator relevance, and development timelines will matter because it will show whether Merck sees TERN-701 as a niche add-on or a serious franchise-building asset.

The broader industry signal is also worth watching. If the Terns Pharmaceuticals acquisition closes smoothly and TERN-701 data continue to support differentiation, it could reinforce confidence in targeted hematology M&A. If the asset disappoints, the deal may become a warning that large pharmaceutical companies are paying aggressively for assets that still carry material clinical uncertainty. In other words, Merck has cleared the easier gate. The real valuation test starts after ownership begins.

Key takeaways on what Merck’s Terns acquisition means for MRK, TERN, and biotech M&A

• Merck & Co., Inc. has reduced transaction uncertainty after the Hart-Scott-Rodino waiting period expired, but closing still depends on tender offer conditions.
• The $53-per-share cash offer has turned Terns Pharmaceuticals stock into a merger-arbitrage story rather than a pure clinical-stage biotech trade.
• TERN-701 gives Merck a targeted hematology asset in chronic myeloid leukemia, but the commercial case depends on differentiation against existing therapies.
• The acquisition supports Merck’s effort to broaden its oncology pipeline before future Keytruda patent pressure becomes more visible to investors.
• Merck’s share price context suggests investors are not dismissing the strategy, but they are also not giving full credit for clinical-stage optionality yet.
• The deal reflects continued appetite among large pharmaceutical companies for precision oncology assets with clear mechanisms and long-term commercial potential.
• Terns Pharmaceuticals shareholders face a trade-off between accepting a cash premium and surrendering potential upside if TERN-701 later delivers stronger data.
• The main execution risks are clinical durability, safety, regulatory design, and whether physicians see enough reason to change chronic myeloid leukemia treatment sequencing.
• The transaction may encourage investor attention toward other hematology-focused biotechnology companies with differentiated targeted therapy pipelines.
• Merck has cleared an important procedural hurdle, but TERN-701 still has to prove that the strategic logic can survive the clinical evidence test.